341 related articles for article (PubMed ID: 25128518)
41. Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.
Bechman K; Tweehuysen L; Garrood T; Scott DL; Cope AP; Galloway JB; Ma MHY
J Rheumatol; 2018 Nov; 45(11):1515-1521. PubMed ID: 30173149
[TBL] [Abstract][Full Text] [Related]
42. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.
Lillegraven S; Prince FH; Shadick NA; Bykerk VP; Lu B; Frits ML; Iannaccone CK; Kvien TK; Haavardsholm EA; Weinblatt ME; Solomon DH
Ann Rheum Dis; 2012 May; 71(5):681-6. PubMed ID: 21994234
[TBL] [Abstract][Full Text] [Related]
43. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis.
McQueen FM; Benton N; Perry D; Crabbe J; Robinson E; Yeoman S; McLean L; Stewart N
Arthritis Rheum; 2003 Jul; 48(7):1814-27. PubMed ID: 12847674
[TBL] [Abstract][Full Text] [Related]
44. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
[TBL] [Abstract][Full Text] [Related]
45. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins.
Graudal N
Scand J Rheumatol Suppl; 2004; 118():1-38. PubMed ID: 15180092
[TBL] [Abstract][Full Text] [Related]
46. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
[TBL] [Abstract][Full Text] [Related]
47. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.
Curtis JR; Flake DD; Weinblatt ME; Shadick NA; Østergaard M; Hetland ML; Brahe CH; Hwang YG; Furst DE; Strand V; Etzel CJ; Pappas DA; Wang X; Hwang CC; Sasso EH; Gutin A; Hitraya E; Lanchbury JS
Rheumatology (Oxford); 2019 May; 58(5):874-883. PubMed ID: 30590790
[TBL] [Abstract][Full Text] [Related]
48. Personalizing treatment targets in rheumatoid arthritis by using a simple prediction model.
de Punder YM; Jansen TL; van Ede AE; den Broeder AA; van Riel PL; Fransen J
J Rheumatol; 2015 Mar; 42(3):398-404. PubMed ID: 25593241
[TBL] [Abstract][Full Text] [Related]
49. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
[TBL] [Abstract][Full Text] [Related]
50. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study.
Hirata S; Dirven L; Shen Y; Centola M; Cavet G; Lems WF; Tanaka Y; Huizinga TW; Allaart CF
Rheumatology (Oxford); 2013 Jul; 52(7):1202-7. PubMed ID: 23392591
[TBL] [Abstract][Full Text] [Related]
51. Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis.
Krabben A; Knevel R; Huizinga TW; Cavet G; van der Helm-van Mil AH
J Rheumatol; 2013 Aug; 40(8):1303-6. PubMed ID: 23729802
[TBL] [Abstract][Full Text] [Related]
52. Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores.
Chernoff D; Scott Eastman P; Hwang CC; Flake DD; Wang X; Kivitz A; Curtis JR
Clin Rheumatol; 2019 Feb; 38(2):437-445. PubMed ID: 30159791
[TBL] [Abstract][Full Text] [Related]
53. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
54. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
55. Early local swelling and tenderness are associated with large-joint damage after 8 years of treatment to target in patients with recent-onset rheumatoid arthritis.
van den Broek M; Dirven L; Kroon HM; Kloppenburg M; Ronday HK; Peeters AJ; Kerstens PJ; Huizinga TW; Lems WF; Allaart CF
J Rheumatol; 2013 May; 40(5):624-9. PubMed ID: 23547212
[TBL] [Abstract][Full Text] [Related]
56. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis.
Verstappen SM; Poole AR; Ionescu M; King LE; Abrahamowicz M; Hofman DM; Bijlsma JW; Lafeber FP;
Arthritis Res Ther; 2006; 8(1):R31. PubMed ID: 16507130
[TBL] [Abstract][Full Text] [Related]
57. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis.
Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Kerstens PJ; Nielen MM; Vos K; van Schaardenburg D; Speyer I; Seys PE; Breedveld FC; Allaart CF; Dijkmans BA
Ann Rheum Dis; 2010 Jan; 69(1):65-9. PubMed ID: 19155234
[TBL] [Abstract][Full Text] [Related]
58. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint.
Meeuwisse CM; van der Linden MP; Rullmann TA; Allaart CF; Nelissen R; Huizinga TW; Garritsen A; Toes RE; van Schaik R; van der Helm-van Mil AH
Arthritis Rheum; 2011 May; 63(5):1265-73. PubMed ID: 21305530
[TBL] [Abstract][Full Text] [Related]
59. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.
Gossec L; Dougados M; Goupille P; Cantagrel A; Sibilia J; Meyer O; Sany J; Daurès JP; Combe B
Ann Rheum Dis; 2004 Jun; 63(6):675-80. PubMed ID: 15140774
[TBL] [Abstract][Full Text] [Related]
60. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy.
Mullan RH; Matthews C; Bresnihan B; FitzGerald O; King L; Poole AR; Fearon U; Veale DJ
Arthritis Rheum; 2007 Sep; 56(9):2919-28. PubMed ID: 17763421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
